Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial Publisher Pubmed



Araminia B1 ; Shalbafan M1 ; Mortezaei A2 ; Shirazi E3 ; Ghaffari S4 ; Sahebolzamani E2 ; Mortazavi SH2 ; Shariati B3 ; Ardebili ME3 ; Aqamolaei A2 ; Naderi S2 ; Akhondzadeh S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, Iran
  3. 3. Mental Health Research Center, School of Behavioral Sciences and Mental Health, Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, Iran
  4. 4. School of Persian Medicine, Iran University of Medical Sciences, Research Institute for Islamic and Complementary Medicine, Tehran, Iran

Source: Journal of Affective Disorders Published:2020


Abstract

Background: Evidence for antidepressant effects of L-Carnosine was shown in some experimental studies. In this study we tried to evaluate the efficacy and tolerability of L-Carnosine combination therapy in treatment of patients with major depressive disorder (MDD). Methods: Fifty-eight patients with MDD (DSM-V) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 400 mg twice daily L-Carnosine or placebo in addition to citalopram (maximum dosage of 40 mg/day) for six weeks in a randomized double-blind, and placebo-controlled study. Patients were assessed using the HAM-D scale at baseline and weeks 2, 4, and 6. Results: Fifty-two patients completed the trial. General linear model repeated measure showed significant difference for time × treatment on HAM-D score [F = 3.17, df = 2.39, p-value = 0.03]. Significantly greater improvement was detected in HAM-D score of the L-Carnosine group compared with the placebo group from baseline to weeks 2, 4 and 6 [Ps = 0.013, 0.028 and 0.023; respectively]. Patients in the L-Carnosine group experienced significantly greater response and remission rate than the placebo group [Ps = 0.023 and 0.012; respectively]. There was no significant difference between the two groups in baseline parameters and frequency of side effects. Limitations: Short follow-up period and small population size were two important limitations of this study. Conclusions: L-Carnosine combination therapy with citalopram can effectively improve symptoms of patients with major depressive disorder. Rapid-onset antidepressant effects of L-Carnosine were also shown which need further investigation. © 2020 Elsevier B.V.
Related Docs
View other Related Docs
1. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials, Iranian Journal of Psychiatry (2022)
2. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
3. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence, Archives of Iranian Medicine (2021)
4. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
5. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
6. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)
7. The Glutamatergic System in Depression: A Review of the Clinical Evidence of Medications and Supplements Affecting Through It, Journal of Iranian Medical Council (2024)
8. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (50)
Farzin Rezaei (6)
Other Related Docs
9. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
10. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
11. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
12. Pentoxifylline for Treatment of Major Depression After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2021)
13. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
14. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
15. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)
16. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)
17. Efficacy of Crocus Sativus (Saffron) in Treatment of Major Depressive Disorder Associated With Post-Menopausal Hot Flashes: A Double-Blind, Randomized, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2018)
18. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)
19. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
20. L-Carnosine As an Adjunctive Therapy to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2018)
21. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
22. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
23. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial, Journal of Alternative and Complementary Medicine (2018)
24. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)
25. Therapeutic Effects of Saffron (Crocus Sativus) Versus Fluoxetine on Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial, Advances in Integrative Medicine (2019)
26. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
27. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
28. Crocus Sativus L. Versus Methylphenidate in Treatment of Children With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study, Journal of Child and Adolescent Psychopharmacology (2019)
29. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
30. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
31. Crocus Sativus L Versus Citalopram in the Treatment of Major Depressive Disorder With Anxious Distress: A Double-Blind, Controlled Clinical Trial, Pharmacopsychiatry (2017)
32. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)
33. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
34. Cilostazol Adjunctive Therapy in Treatment of Negative Symptoms in Chronic Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study, Human Psychopharmacology (2017)
35. Evidence for Anti-Inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial, Clinical Neuropharmacology (2022)
36. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Children With Attention-Deficit/Hyperactivity Disorder: Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2019)
37. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
38. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
39. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
40. Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2019)
41. Red Yeast Rice As an Adjunct to Sertraline for Treatment of Depression in Patients With Percutaneous Coronary Intervention: Placebo-Controlled Trial, Advances in Integrative Medicine (2018)
42. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)
43. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, International Journal of Neuropsychopharmacology (2020)
44. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review, Journal of Medicinal Plants (2019)
45. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)
46. Psychotropic Effects of Saffron: A Brief Evidence-Based Overview of the Interaction Between a Persian Herb and Mental Health, Journal of Iranian Medical Council (2021)
47. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
48. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
49. Therapeutic Application of Saffron for Improvement of Women’S Health: A Review of Literature, Journal of Iranian Medical Council (2021)
50. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)